RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 11:25:49(美东 10-25 23:25)·⟳ 抓取 11:28:48 +2m59s·⚡ 决策 10-26 11:30:13 +1m25s·1.2 天前
罗氏 divarasib III期 Krascendo 1 头对头优效数据经 RTTNews 再转述，无新增事实
本条 RTTNews 报道与 72 小时内已处理的 globenewswire/ESMO-NEJM 同一催化（divarasib Krascendo 1 完整数据）完全重合，关键数字（44% 死亡风险下降、OS 18 vs 12 个月、PFS HR、ORR 58% vs 32%）一致，无任何新增金额、监管进展或官方修正；且顶线优效早在 2026-07-02 公告、Q2 已上调峰值指引，属旧闻二次转述，已被处理并判 PRICE_IN。
📄 原文RTTNews Biotech↗ 原文
Roche's Divarasib Cuts Death Risk By 44% In KRAS G12C-Mutated Lung Cancer Phase III Trial
Roche Holding AG (RHHBY) announced positive pivotal results from its Phase III Krascendo 1 study, showing that investig…
不做 Roche Holding AG（RHHBY.US）
同一 divarasib Krascendo 1 催化约 12 小时前已处理：顶线 2026-07-02 已公告、Q2 已上调峰值指引，10-25 ESMO/NEJM 完整数据后本条 RTTNews 无任何新增事实（NO_INCREMENTAL_FACT，已充分 price-in）；且罗氏为超大盘药企、主体为 OTC ADR（RHHBY）/SIX 主板行情支持差，单一管线相对市值增量小，无可执行预期差。
不做 Amgen（AMGN.US）
sotorasib 头对头劣效带来份额压力，但该单品在安进约千亿美元级市值中占比很小，且为旧数据二次传播，做空强度与新鲜度均不满足红线。
不做 Bristol-Myers Squibb（BMY.US）
adagrasib 同为被超越的一代对照药，但单品对 BMS 体量贡献有限、无新增负面事实，缺乏可交易的做空 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
RTTNews 这条只是罗氏 divarasib 头对头 III 期阳性数据的媒体二次转述，源头为 10-25 ESMO/NEJM 完整数据、顶线更已于 7-02 公布；同一催化约 12 小时前已判定不做（已 price-in + 主体 OTC/SIX 不可执行 + 对手方单品占比过小），本条无新增事实，维持不做。
🔎 新鲜度:最早出现 2026-07-02 · 扩散 high · price-in 风险 high ↗
关键理由
- 数据本身具 best-in-class 潜力，但增量信息在 2026-07-02 顶线公告与 10-25 ESMO/NEJM 完整公布时已释放，本条仅为 RTTNews 改写。
- 罗氏为超大盘药企，单一 NSCLC 管线对整体市值增量有限；竞争对手安进/BMS 的受冲击单品占各自市值比例小，多空两侧均无足够 edge。
主要风险
- 若后续出现全新事实（FDA 提交/批准时间表、具体峰值销售上修、合作方授权变动），需作为新事件重新研判。
- 周一美股开盘罗氏 ADR 或竞品仍可能有情绪性波动，但不构成可执行的预期差交易。
先例如何影响了这次决策
对本次决策的影响:未改变结论：维持 AVOID，重复消息不再展开行情与先例研究。
方向:未做外部先例统计：本条因与已处理事件重复、无新增事实而早停，先例不会改变重复判定。
涨幅量级:无适用幅度校准；同一催化的前次决策已基于 price-in 与不可执行性判定不做。
形态:不适用
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 114 ms
{"result": "search_processed_events:agent query=`divarasib 44% death risk reduction overall survival sotorasib adagrasib head-to-head | roche divarasib krascendo 1 phase iii kras g12c lung cancer | 罗氏 divarasib kras g12c 三期 总生存期`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 67.2/72 小时、1167 条本臂决策(完整)，返回 1 条候选。\n• 10-25
原文全文
展开原文 · 2,622 字
Roche Holding AG (RHHBY) announced positive pivotal results from its Phase III Krascendo 1 study, showing that investigational therapy divarasib significantly outperformed currently approved KRAS G12C inhibitors in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).
The study met its primary and key secondary endpoints, with divarasib demonstrating statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) compared with first-generation KRAS G12C inhibitors sotorasib and adagrasib.
Patients treated with divarasib experienced a 44% reduction in the risk of death, while median overall survival reached approximately 18 months, compared with 12 months in the control arm. The investigational drug also reduced the risk of disease progression or death by 42% versus the comparator therapies.
The survival and disease-control benefits were consistent across clinically relevant patient subgroups, including those defined by PD-L1 expression levels and KEAP1 mutation status. In addition, the objective response rate (ORR) with divarasib was nearly twice that achieved with sotorasib or adagrasib.
Safety findings remained consistent with previous studies, and no new safety signals were identified. Roche said the most common treatment-related adverse events were generally low grade and manageable.
The Krascendo 1 trial is the first head-to-head Phase III study comparing a next-generation KRAS G12C inhibitor against approved first-generation therapies. The results strengthen divarasib's potential to become a new standard treatment option for patients with KRAS G12C-mutated NSCLC whose disease has progressed following prior therapy.
Roche is currently advancing a broad Phase III clinical development program evaluating divarasib both as a standalone treatment and in chemotherapy-free combinations across multiple stages and lines of NSCLC therapy. The U.S. Food and Drug Administration previously granted Breakthrough Therapy Designation to divarasib in 2022 and awarded Orphan Drug Designation for KRAS G12C-mutated NSCLC in 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
The study met its primary and key secondary endpoints, with divarasib demonstrating statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) compared with first-generation KRAS G12C inhibitors sotorasib and adagrasib.
Patients treated with divarasib experienced a 44% reduction in the risk of death, while median overall survival reached approximately 18 months, compared with 12 months in the control arm. The investigational drug also reduced the risk of disease progression or death by 42% versus the comparator therapies.
The survival and disease-control benefits were consistent across clinically relevant patient subgroups, including those defined by PD-L1 expression levels and KEAP1 mutation status. In addition, the objective response rate (ORR) with divarasib was nearly twice that achieved with sotorasib or adagrasib.
Safety findings remained consistent with previous studies, and no new safety signals were identified. Roche said the most common treatment-related adverse events were generally low grade and manageable.
The Krascendo 1 trial is the first head-to-head Phase III study comparing a next-generation KRAS G12C inhibitor against approved first-generation therapies. The results strengthen divarasib's potential to become a new standard treatment option for patients with KRAS G12C-mutated NSCLC whose disease has progressed following prior therapy.
Roche is currently advancing a broad Phase III clinical development program evaluating divarasib both as a standalone treatment and in chemotherapy-free combinations across multiple stages and lines of NSCLC therapy. The U.S. Food and Drug Administration previously granted Breakthrough Therapy Designation to divarasib in 2022 and awarded Orphan Drug Designation for KRAS G12C-mutated NSCLC in 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
214b1c1753· 2026-10-26 11:30 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前